{"id":11996,"date":"2019-08-25T09:31:48","date_gmt":"2019-08-25T09:31:48","guid":{"rendered":"https:\/\/iach2019.cme-congresses.com\/?page_id=11996"},"modified":"2019-09-18T20:41:23","modified_gmt":"2019-09-18T20:41:23","slug":"supporters","status":"publish","type":"page","link":"https:\/\/iach2019.cme-congresses.com\/supporters\/","title":{"rendered":"Supporters & Exhibitors"},"content":{"rendered":"

\n\t\t\t\t\t
\n\t\t\t\t\t\t

Supporters & Exhibitors<\/h2><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Platinum<\/span><\/h3>
<\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Jazz Pharmaceuticals<\/h3><\/div>

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options, so they can live their lives more fully and redefine what is possible. As a leader in sleep medicine and with a growing hematology\/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines.<\/p>\n

Jazz Pharmaceuticals
\nWing B, Building 5700, Spires House, John Smith Drive, Oxford Business Park South, Oxford, OX4 2RW
\nPhone: +44 1865 405000
\nWebsite: www.jazzpharmaceuticals.com<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Silver<\/span><\/h3>
<\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Janssen<\/h3><\/div>

Janssen is working to change what a cancer diagnosis means so that one day the words \u201cyou have cancer\u201d will be less terrifying for patients to hear and less distressing for physicians to say. We aim to make cancer a manageable, even curable, condition.<\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Supporters<\/span><\/h3>
<\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Abbvie<\/h3><\/div>

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company\u2019s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world\u2019s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com<\/a>. Follow @abbvie<\/a> on Twitter or view careers on our Facebook<\/a> or LinkedIn<\/a> page.<\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div>
<\/div>
<\/div>
\"\"<\/span><\/div>
<\/div>
<\/div>

in partnership with ATERHIT to support IACH 2019<\/em><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

ATERHIT<\/h3><\/div>

The Association for Training, Education and Research in Hematology, Immunology and Transplantation (ATERHIT) is a non-for profit scientific organization based in Paris (France).
\nATERHIT aims to promote clinical, translational and basis research in the fields of hematology, immunology and stem cell transplantation through direct or indirect support to research projects. It also organizes a board portfolio of educational activities with the goal to disseminate knowledge in its fields of interest and enhance collaborations among all stakeholders. ATERHIT provides support for students, fellows, junior doctors, nurses, and other healthcare professionals who wish to train or gain more experience in this field. The organization can distribute prizes to acknowledge some major achievements in these fields.<\/p>\n

Mailing address:
\nH\u00f4pital Saint Antoine, Service h\u00e9matologie,
\n184 rue du Faubourg Saint Antoine,
\n75012 PARIS, France<\/p>\n

Tel:\u00a002 40 09 72 26 or 06 59 66 34 07
\nEmail: aterhit@yahoo.fr<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Celgene<\/h3><\/div>

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.<\/p>\n

US Corporate Headquarters<\/strong>
\nCelgene Corporate Headquarters
\n86 Morris Avenue
\nSummit, NJ 07901
\nPhone: +1 908-673-9000
\nFax: +1 908-673-9001
\nWebsite : www.celgene.com<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

CSL Behring<\/h3><\/div>

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. For over 100 years, we have put patients first by delivering on our promise to discover, develop and deliver new and innovative life-changing therapies that address the world\u2019s most serious, complicated and rare disorders. We’re now bringing that same commitment to transplantation. Our mission is to address unmet patient needs before, during, and after transplantation, to enable patients to get the very most out of the gift of life.<\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Daiichi Sankyo<\/h3><\/div>

Daiichi Sankyo and its 15,000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical products. Our European headquarters are in Munich, Germany and we have affiliates in 12 European countries. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, our mission is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise (ADC), Acute Myeloid Leukemia Franchise (AML) and Breakthrough Science Franchise (BS), we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025. www.daiichi-sankyo.eu<\/a>.<\/p>\n

Daiichi Sankyo Oncology France<\/strong>
\nImmeuble le Corosa
\n1 rue Eug\u00e8ne et Armand Peugeot
\n92508 Rueil-Malmaison, Frankreich
\nTelefon: +33 1 55 62 14 60
\nFax: +33 1 55 62 14 61
\ninfos@daiichi-sankyo.fr<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Karyopharm<\/h3><\/div>

Karyopharm Therapeutics is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm\u2019s lead compound, XPOVIOTM<\/sup> (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, Karyopharm\u2019s compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.<\/p>\n

US-NON-08\/18-00002<\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd)<\/h3><\/div>

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical\u202fproducts and therapies. Our Specialty Brands segment includes branded medicines\u202fand\u202fthe Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.\u202fMallinckrodt is the only provider of integrated systems for the delivery of Extracorporeal\u202fPhotopheresis\u202f(ECP).\u202fTo learn more about this product, visit\u202fwww.therakos.co.uk<\/a>.<\/p>\n

Company name: Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd)
\nMailing address: 3 Lotus Park, The Causeway, Staines-upon-Thames TW18 3AG, UK
\nPhone: +44 (0) 1784 636 700
\nFax: none to share for sales purposes ( we only have faxes for customer service and hotline)
\nEmail: CritCareTKS-TKSInfo@mnk.com<\/a>
\nUrl: www.therakos.co.uk<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Medac<\/h3><\/div>

Medac is a German company founded in 1970. Today, medac is present in all European countries as well as in the United States and in Asia.
\nBased in Hamburg, medac is a major player in the development, manufacture and marketing of pharmaceutical specialties in various fields such as rheumatology, urology, oncology, hematology and neurosurgery. With a portfolio of innovative medicines, generic generic and value-added generics, medac is a laboratory halfway between originator and generic laboratories.<\/p>\n

Adress: Medac , 23 rue Pierre Gilles de Gennes 69007 Lyon
\ncontact : Tel 04 37 66 14 70
\nFax : 04 37 66 28 78
\ncontact@medac.fr<\/a>
\nwww.medac.fr<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t
\"\"<\/span><\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Sheba<\/h3><\/div>

Established in 1948, Sheba Medical Center is now the leading medical center in Israel and an internationally recognized healthcare facility. In 2019, Newsweek magazine ranked Sheba on their prestigious list of the top ten hospitals worldwide. Located on a comprehensive campus, Sheba offers a wide range of medical divisions and specialties. Our highly qualified doctors are involved in many innovative treatments and cutting-edge research programs to advance the clinical care of patients everywhere. Sheba also functions as a tertiary care center and accepts referrals of complex cases from throughout the region and the world.<\/p>\n

International Medical Tourism Division at the Chaim Sheba Medical Center
\nPhone: +972-3-5303100
\nFax: +972-3-5308040
\nEmail: Mika.Amram@sheba.health.gov.il<\/a>
\nWeb: www.shebaonline.org<\/a><\/p>\n<\/div><\/div><\/div>

<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t

Exhibitors<\/span><\/h3>
<\/div><\/div><\/div>
<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>
\n\t\t\t\t\t
\n\t\t\t\t\t\t